Cargando…
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
OBJECTIVES: Aberrant PI3K/AKT/mTOR activation is common in gynaecological malignancies. However, predictive biomarkers of response to PI3K pathway inhibitors (PAMi) have yet to be identified. METHODS: We analysed the outcomes of patients with advanced gynaecological cancer with available genomic dat...
Autores principales: | Rodriguez-Freixinos, Victor, Ruiz-Pace, Fiorella, Fariñas-Madrid, Lorena, Garrido-Castro, Ana Christina, Villacampa, Guillermo, Nuciforo, Paolo, Vivancos, Ana, Dienstmann, Rodrigo, Oaknin, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435251/ https://www.ncbi.nlm.nih.gov/pubmed/30962959 http://dx.doi.org/10.1136/esmoopen-2018-000444 |
Ejemplares similares
-
Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
por: Serna, Garazi, et al.
Publicado: (2019) -
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
por: Poveda, Andres, et al.
Publicado: (2021) -
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
por: Poveda, Andres, et al.
Publicado: (2022) -
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
por: Dienstmann, Rodrigo, et al.
Publicado: (2020) -
Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)